Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
Transfus Apher Sci
.
2021 Jun;60(3):103105.
doi: 10.1016/j.transci.2021.103105.
Epub 2021 Feb 20.
Authors
Carlo Gambacorti-Passerini
1
,
Marco Ruggeri
2
,
Andrea Aroldi
3
,
Rocco Piazza
3
,
Angela Mazzi
4
,
Giustina De Silvestro
5
,
Mauro Krampera
6
,
Francesco Lanza
7
Affiliations
1
University of Milano-Bicocca, Monza, Italy; Hematology Division, ASST Monza, Italy. Electronic address: carlo.gambacorti@unimib.it.
2
Division of Hematology, San Bortolo Hospital, Vicenza, Italy.
3
University of Milano-Bicocca, Monza, Italy; Hematology Division, ASST Monza, Italy.
4
Transfusion Medicine Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.
5
Blood Transfusion Service, Apheresis Unit, University Hospital of Padova, Italy.
6
Section of Hematology, Department of Medicine, University of Verona, Policlinico G.B. Rossi, Verona, Italy.
7
Hematology Service, Hospital of Ravenna, Ravenna, Italy.
PMID:
33637468
PMCID:
PMC7896506
DOI:
10.1016/j.transci.2021.103105
No abstract available
MeSH terms
Blood Donors*
Blood Transfusion / methods*
COVID-19 / blood*
Female
Hematologic Neoplasms / therapy*
Humans
Male
SARS-CoV-2 / isolation & purification